March 3 (Reuters) - The U.S. Food and Drug Administration has warned 30 telehealth companies for making false or misleading claims about compounded versions of GLP‑1 drugs, the agency said on Tuesday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.